-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 12, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of

-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 10, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration ( FDA ) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug

Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lymphoma Analyses Describe ADCETRIS Activity in T-Cell and B-Cell Non-Hodgkin Lymphomas Across All Levels of CD30

- First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO

BOTHELL, Wash. --(BUSINESS WIRE)--May 21, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G. Taylor , M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of

First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3 rd BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its

BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time . The presentation will be webcast live and available

-Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial Results- -Supplemental New Drug Submission Completed for ADCETRIS in Combination with CHP Chemotherapy in Frontline

-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018- -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned

BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 4, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference